NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-02 18:03இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Acutaas Chemicals released its Q2 FY27 earnings call transcript, highlighting strong operational performance with Q2 revenue up 42.7% YoY to Rs 436.9 crore (Rs 4,369 million). Management upgraded its full-year FY27 revenue growth guidance from 25% to around 30% and guided for 38%-40% EBITDA margins. The company preponed its Rs 1,000 crore CDMO revenue target from FY28 to FY27, and set a new milestone of Rs 2,000 crore CDMO revenue by FY30. Additionally, commercial revenues commenced in the Battery Chemicals vertical, and full-year FY27 capex is projected at around Rs 300 crore (Rs 3,000 million).
உச்சம் நம்பிக்கை
என்ன மாறியதுAcutaas preponed its Rs 1,000 crore CDMO revenue goal to FY27, raised FY27 growth guidance to ~30%, and reported initial commercial dispatches in battery chemicals.
ஏன் இது முக்கியம்Higher CDMO visibility and rapid commercialization of battery and electronic-grade chemicals expand high-margin addressable markets beyond generic pharma intermediates.
📅 குறுகிய காலம்Positive sentiment likely to be sustained by upgraded full-year growth guidance and preponement of milestone CDMO targets.
📈 நீண்ட காலம்Expansion into semiconductor chemicals in South Korea and scaling battery electrolyte additives provide structural diversification and high-margin CDMO visibility towards the Rs 2,000 crore FY30 target.
⚠ அபாய எச்சரிக்கைகள்
Customer concentration risk in CDMO where commercial scale depends on innovative customers' drug performance.
Specialty Chemicals vertical remains volatile during the exit from low-margin commodity products.
Execution and qualification delays for semiconductor and electronic-grade chemical facilities.
👀 கவனிக்க வேண்டியவை
Track the ramp-up of commercial battery chemical shipments and semiconductor qualifications in South Korea over H2 FY27, alongside monitoring EBITDA margins against the guided 38%-40% band.
Q2 FY27 PAT Jumps 71.4% YoY to ₹123.1 Cr; FY27 Revenue Growth Guidance Raised to ~30%
Acutaas Chemicals reported strong Q2 FY27 results with revenue growing 42.7% YoY to ₹436.9 Cr (₹4,369 Mn) and net profit increasing 71.4% YoY to ₹123.1 Cr (₹1,231 Mn). EBITDA margins expanded by 920 bps YoY to 40.3%, supported by gross margin gains and operating leverage in the Advance Intermediates business. Management raised its full-year FY27 revenue growth guidance from 25% to ~30% and EBITDA margin guidance to 38-40%. Additionally, the company inaugurated its South Korea manufacturing facility ahead of schedule to serve the semiconductor specialty chemicals market.
உச்சம் நம்பிக்கை
என்ன மாறியதுAcutaas delivered strong Q2 FY27 growth, inaugurated its South Korean manufacturing plant ahead of schedule, and officially upgraded both its full-year revenue and margin guidance.
ஏன் இது முக்கியம்The performance underscores strong pricing leverage and demand in core CDMO and pharma intermediates, while the Korean unit accelerates entry into higher-value semiconductor chemicals.
📅 குறுகிய காலம்Positive market sentiment driven by the double beat on operating margins and an upward revision in full-year guidance.
📈 நீண்ட காலம்Expansion into semiconductor photoresists and high-purity chemicals via the South Korea facility diversifies the business away from pure generic intermediates into high-entry-barrier segments.
⚠ அபாய எச்சரிக்கைகள்
Specialty chemicals segment declined 20.0% YoY in Q2 FY27, partly affected by ownership changes at a US customer
High raw material dependence with raw materials historically accounting for a substantial portion of sales costs
👀 கவனிக்க வேண்டியவை
Track the ramp-up and commercial contributions from the newly inaugurated South Korea semiconductor chemical facility and watch whether EBITDA margins sustain the revised 38-40% guidance in upcoming quarters.
Acutaas Chemicals Q2 FY27 Standalone PAT Up 86% YoY to ₹135.7 Cr; Indichem Plant Inaugurated
Acutaas Chemicals reported strong Q2 FY27 standalone results with revenue from operations growing 24.5% YoY to ₹380.09 Cr (vs ₹305.19 Cr in Q2 FY26) and net profit rising 86.2% YoY to ₹135.74 Cr. Half-year standalone PAT reached ₹211.63 Cr compared to ₹117.54 Cr in H1 FY26. Operationally, its step-down subsidiary Indichem Inc. inaugurated its semiconductor materials plant in South Korea on August 28, 2026, following a ~₹200 Cr (KRW 30 billion) investment, currently under trial runs. The company also streamlined corporate structure by making Enchem Ami Organics a direct wholly owned subsidiary on October 17, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுAcutaas posted robust Q2 earnings with an 86% YoY standalone net profit jump and announced the completion/trial runs of its South Korean semiconductor facility.
ஏன் இது முக்கியம்The earnings demonstrate strong operating leverage, while commercializing semiconductor chemicals through Indichem diversifies operations beyond traditional pharma intermediates into high-value electronics.
📅 குறுகிய காலம்Market sentiment should react favorably to the strong YoY PAT acceleration and progress on trial runs at the Korean semiconductor materials facility.
📈 நீண்ட காலம்Entry into semiconductor specialty materials alongside CDMO scale-up positions the company for higher-margin revenue streams, diversifying beyond base pharmaceutical intermediates.
⚠ அபாய எச்சரிக்கைகள்
Commercialization and ramp-up risks at the newly inaugurated South Korean semiconductor plant.
Raw material price sensitivity given historic exposure of ~72% of sales to raw materials.
👀 கவனிக்க வேண்டியவை
Track the commercialization timeline and revenue contribution of the South Korea Indichem plant following trial runs, alongside operating margin sustainability.
Acutaas Chemicals Inaugurates OEB 4 Pilot Plant at Sachin for High-Potency API Intermediates
Acutaas Chemicals Limited (formerly Ami Organics Limited) has inaugurated a new pilot plant at its Unit 1 facility in Sachin, Surat on September 4, 2026. The plant includes a dedicated area designed for Occupational Exposure Band (OEB) 4 containment, allowing scale-up and development of highly potent intermediates for high-potency APIs (HPAPIs). The facility will also support R&D trials and validations for new pipeline products. While specific capex figures were not disclosed, this enhances the company's CDMO capabilities in higher-margin potent compounds against its TTM revenue base of Rs 843 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுAcutaas Chemicals has commissioned a specialized OEB 4 pilot plant at Sachin, Surat to expand R&D and scale-up capabilities for high-potency API intermediates.
ஏன் இது முக்கியம்OEB 4 containment capabilities allow the company to move up the value chain into complex, high-potency molecules, supporting long-term margins and CDMO client acquisition.
Inauguration Date: செப்டம்பர் 4, 2026Containment Standard: OEB 4Location: Unit 1 - Sachin, SuratCapex Outlay: வெளியிடப்படவில்லைTTM Revenue Context: Rs 843 கோடி
📅 குறுகிய காலம்Positive for sentiment as it demonstrates ongoing R&D infrastructure build-up, though direct near-term revenue impact will depend on client trials and validation cycles.
📈 நீண்ட காலம்Strengthens competitive moat in custom synthesis and CDMO for potent oncology/specialty drugs, potentially driving margin expansion over the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
Commercialization gestation timelines for HPAPI intermediates can be lengthy
Capex outlay and exact capacity additions were not disclosed
👀 கவனிக்க வேண்டியவை
Track management commentary in upcoming quarterly calls regarding CDMO pipeline conversions, client validation timelines, and revenue contribution from high-potency molecules.
Acutaas Chemicals Sets Sep 17, 2026 Record Date for ₹2.50/Share Final Dividend
Acutaas Chemicals Limited has fixed Thursday, September 17, 2026, as the record date to determine shareholder eligibility for a final dividend of ₹2.50 per equity share (50% on face value of ₹5) for FY 2025-26. The dividend is subject to shareholder approval at the upcoming 19th Annual General Meeting scheduled for September 24, 2026. Once approved, the payout will be completed within 30 days of the AGM declaration.
உச்சம் நம்பிக்கை
என்ன மாறியதுAcutaas Chemicals announced the formal record date and AGM timeline for its FY26 final dividend payout.
ஏன் இது முக்கியம்Confirms the cash distribution timeline for eligible shareholders; the ₹2.50 payout represents a modest dividend yield relative to the current market price of ₹3,281.60.
Final dividend per share: Rs. 2.50/-Dividend percentage: 50%முக மதிப்பு: Rs. 5/-ரெக்கார்ட் தேதி: 17-செப்.-2026AGM date: 24-செப்.-2026
📅 குறுகிய காலம்Ex-dividend price adjustment will take place around September 16-17, 2026, with minimal impact on trading momentum given the low yield.
📈 நீண்ட காலம்Limited; this is a standard corporate action reflecting regular cash distribution policy.
👀 கவனிக்க வேண்டியவை
Investors seeking dividend eligibility must hold shares before the ex-dividend date preceding September 17, 2026, and track shareholder voting outcomes at the AGM on September 24, 2026.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Acutaas Subsidiary Inaugurates ~₹200 Cr Semiconductor Materials Plant in South Korea
Acutaas Chemicals' step-down subsidiary, Indichem Inc., has inaugurated its semiconductor materials plant in Gongju, South Korea. Acutaas Advance Material Limited holds a 75% stake in Indichem and has invested KRW 30 billion (approx. ₹200 crore), representing ~23.7% of Acutaas' TTM revenue of ₹843 crore. Completed in 11 months, the facility spans 16,513.7 sq. m. and utilizes a two-country model where chemicals are synthesised in India and refined to semiconductor grade (parts-per-billion purity) in Korea close to customer clusters.
உச்சம் நம்பிக்கை
என்ன மாறியதுIndichem Inc. transitioned from construction to operational status with the inauguration of its Gongju semiconductor materials plant.
ஏன் இது முக்கியம்Enables Acutaas to scale high-margin semiconductor and display specialty chemicals by synthesizing in India and refining locally for Korean semiconductor giants.
Investment by Acutaas (AAML): KRW 30 billion (approx. ₹200 crore)Investment vs TTM revenue: ~23.7%Acutaas subsidiary equity stake: 75%Facility land area: 16,513.7 sq. m.Construction turnaround: 11 மாதங்கள்
📅 குறுகிய காலம்Positive sentiment driver highlighting disciplined project execution and entry into the high-value semiconductor supply chain.
📈 நீண்ட காலம்High structural significance as commercialization of semiconductor chemicals provides product diversification away from pure pharma intermediates and unlocks new export revenue streams.
⚠ அபாய எச்சரிக்கைகள்
Customer qualification lead times in semiconductor-grade chemicals can be lengthy
Rising goodwill amortisation / carrying value risks from overseas subsidiary investment
Acutaas Chemicals has approved a capital expenditure plan of up to ₹212 crore to set up a greenfield/brownfield manufacturing facility in Gujarat for new electronic grade chemicals. The proposed plant will have an annual capacity of up to 81,000 MT per annum and is scheduled to be completed by the end of FY 2027-28. The capex, representing ~25.1% of TTM revenue (₹843 crore), will be funded via internal accruals, bank financing, or other permissible methods. Additionally, the Board approved the re-appointment of two directors and extended the ESOS 2023 scheme to Indian subsidiary employees.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Board approved a major ₹212 crore expansion into electronic grade chemicals and extended ESOS benefits to subsidiary staff.
ஏன் இது முக்கியம்The ₹212 crore capex (~25.1% of TTM revenue) enters a high-growth, high-value specialty chemical segment (electronic/semiconductor grade), diversifying away from core pharma intermediates.
Capex Outlay: Up to Rs. 212 croresProposed Capacity: Upto 81,000 MT per annumCapex vs TTM Revenue: ~25.1%Target Commissioning: By the end of FY 2027-28AGM Date: செப்டம்பர் 24, 2026
📅 குறுகிய காலம்Positive sentiment driver as the company formalizes entry into electronic chemicals, though operational impact is medium-to-long term.
📈 நீண்ட காலம்Enhances revenue diversification and margin potential through electronic grade specialty chemical supplies by FY28.
⚠ அபாய எச்சரிக்கைகள்
Project execution and commissioning delays before FY28
👀 கவனிக்க வேண்டியவை
Track progress on land acquisition, environmental clearances, financing closure, and execution updates toward the FY28 target commissioning.
Acutaas Chemicals Limited has received formal approval under the Ministry of Electronics and Information Technology's (MeitY) Electronics Components Manufacturing Scheme (ECMS). The approval applies to its Electrolyte Additives manufacturing business located at Jhagadia, Gujarat. Total cumulative project investment is ₹256.47 crores (~30.4% of TTM revenue), with ₹119.12 crores qualifying as eligible investment. Under the scheme, Acutaas is eligible to receive incentives of up to 25% on the eligible investment (approx. ₹29.78 crores) over a 5-year period ending in FY 2030-31.
உச்சம் நம்பிக்கை
என்ன மாறியதுAcutaas secured MeitY approval under the ECMS scheme, entitling its battery electrolyte project to central government capital/production incentives.
ஏன் இது முக்கியம்The subsidy improves capital efficiency and project return metrics for the company's high-value diversification into EV battery and electronics chemicals.
Cumulative project capex: ரூ. 256.47 கோடிEligible ECMS investment: ரூ. 119.12 கோடிCapex vs TTM revenue: ~30.4%Max incentive percentage: upto 25%Benefit period: up to FY 2030-31
📅 குறுகிய காலம்Positive sentiment driver as formal government endorsement and fiscal incentives lower net investment outlays.
📈 நீண்ட காலம்Strengthens competitiveness in import-substitution battery chemistry, enhancing operating leverage as commercial volumes scale through FY31.
⚠ அபாய எச்சரிக்கைகள்
Incentive realization is subject to continuous compliance with scheme guidelines and investment milestones
Ramp-up dependent on domestic and global EV battery demand
👀 கவனிக்க வேண்டியவை
Track the commercial production ramp-up of the Jhagadia electrolyte additives plant and verify whether incentive milestones are met in upcoming annual disclosures.
Acutaas Chemicals reported a robust Q1 FY27 with revenue reaching ₹329.7 crore, a 59.1% YoY increase, primarily driven by a 76.5% surge in the Pharma Intermediates segment. The company has successfully transitioned from trial runs to commercial supply for its battery chemicals plant, targeting a rapid ramp-up. While the Specialty Chemicals segment saw a 10.6% YoY decline due to the deliberate phasing out of low-margin commodity chemicals, gross margins expanded by 466 bps to 57.9%. Management has maintained a full-year revenue growth guidance of 25% with stable margins.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has officially commenced commercial supply of battery chemicals and is actively shifting its Specialty Chemicals portfolio away from commodity products toward higher-margin semiconductor and battery materials.
ஏன் இது முக்கியம்The shift towards CDMO and high-tech specialty chemicals (EV batteries/semiconductors) represents a structural move to higher-value products, which could sustain the current high P/E multiple if growth targets are met.
📅 குறுகிய காலம்The strong revenue beat and margin expansion in Q1 are likely to be viewed positively by the market in the coming weeks.
📈 நீண்ட காலம்The successful commercialization of battery and semiconductor chemicals provides a new growth engine beyond traditional pharma intermediates, potentially diversifying the revenue base over the next 3 years.
⚠ அபாய எச்சரிக்கைகள்
21% dependency on Chinese imports for raw materials
High customer concentration in specific CDMO molecules
Geopolitical tensions in the Gulf impacting logistics
👀 கவனிக்க வேண்டியவை
Watch for the execution and volume ramp-up in the battery chemicals and semiconductor segments over the next 2-3 quarters to see if they can offset the planned phase-out of commodity chemicals.
59.1% Revenue Growth in Q1 FY27; EBITDA Margins Expand to 34.3%
Acutaas Chemicals reported a strong start to FY27 with revenue growing 59.1% YoY to ₹329.7 crore, primarily driven by the Advance Intermediates segment which grew 76.5%. EBITDA surged 122.1% to ₹113.1 crore, with margins expanding significantly by 970 bps to 34.3% due to better product mix and operational efficiencies. PAT increased 70.4% to ₹75 crore, despite a sharp drop in other income to ₹1.8 crore from ₹15.9 crore YoY. The management maintained a full-year revenue growth guidance of 25%, suggesting a potential conservative outlook given the strong Q1 performance.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 financial results, highlighting a significant jump in profitability and a shift in revenue mix towards Advance Intermediates.
ஏன் இது முக்கியம்The sharp margin expansion indicates successful execution in the high-value CDMO business and improved operational efficiency, which could lead to a valuation re-rating if these levels are maintained.
📅 குறுகிய காலம்The stock may react positively to the strong YoY growth and significant margin expansion, although the sequential (QoQ) decline in PAT might temper enthusiasm.
📈 நீண்ட காலம்The structural shift towards CDMO and entry into semiconductor/battery chemicals provides a long-term growth runway, supported by a 25% guided CAGR.
⚠ அபாய எச்சரிக்கைகள்
21% dependency on Chinese imports for raw materials
High customer concentration
Significant sequential (QoQ) decline in PAT (44.2%)
👀 கவனிக்க வேண்டியவை
Monitor the sustainability of the 34.3% EBITDA margin in upcoming quarters, as it significantly exceeds the FY25 average of 23%. Watch for the commercialization progress of semiconductor chemicals and electrolyte additives which are expected to ramp up in FY26-27.
Q1 Revenue up 59% YoY to ₹329.7 Cr; PAT rises 70% to ₹75 Cr
Acutaas Chemicals (formerly Ami Organics) reported strong YoY growth for Q1 FY27, with consolidated revenue increasing 59% to ₹329.7 Cr compared to ₹207.2 Cr in the same quarter last year. Net profit grew 70% YoY to ₹75 Cr, though it declined sequentially from ₹134.3 Cr in Q4 FY26. The company disclosed a 10% dilution in its electrolyte subsidiary (ACEPL) following a preferential issue to A.R.Z Pharma Ltd. Additionally, a GST inspection was conducted at the Surat facility in June 2026, which management expects will have no material financial impact.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned to a higher revenue base YoY and introduced a strategic partner in its electrolyte subsidiary, while also undergoing a routine but notable regulatory inspection.
ஏன் இது முக்கியம்The strong YoY growth validates the company's expansion into specialty chemicals and CDMO, though the sequential dip highlights the quarterly volatility inherent in large contract-based pharma businesses.
📅 குறுகிய காலம்The market is likely to react positively to the robust YoY growth, although the sequential decline and the mention of a GST search may lead to some caution.
📈 நீண்ட காலம்The company's structural shift toward semiconductor chemicals and battery electrolytes, supported by strategic partnerships, remains a key long-term growth driver.
⚠ அபாய எச்சரிக்கைகள்
GST inspection outcome pending final assessment
Sequential revenue decline of 23.8%
High raw material dependency (50.3% of revenue)
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of the electrolyte business following the strategic stake sale in ACEPL and watch for any further updates regarding the GST inspection outcome.
Acutaas Chemicals: CGST Anti-Evasion Search Concludes at Surat Facilities
Acutaas Chemicals Limited has reported the conclusion of a search operation by the Central Goods & Service Tax (CGST) & Central Excise Anti-evasion Department, Surat. The inspection, conducted under Section 67(2) of the CGST Act, 2017, took place at the company's registered office and manufacturing unit in Sachin, Surat. As of June 23, 2026, the search has concluded, and the company states that no official document or demand has been issued by the department. Management has clarified that the event has no material impact on the company's financial or operational performance.
முக்கிய அம்சங்கள்
Search conducted by the Additional Commissioner of CGST & CE, Anti-evasion Department, Surat.Inspection concluded on June 23, 2026, at approximately 10:45 a.m. following an initial start on June 22.The search targeted both the Registered Office and the manufacturing unit situated at GIDC Sachin, Surat.No official violation notice or document has been issued by the CGST department following the search.Company confirms zero material impact on financials, operations, or other activities at this stage.
👀 கவனிக்க வேண்டியவை
Investors should remain cautious and watch for subsequent disclosures regarding any potential tax demands or penalties that may arise from this inspection. While current impact is nil, the involvement of the anti-evasion wing necessitates monitoring for further legal developments.
Acutaas Chemicals Dilutes 10% Stake in Subsidiary ACEPL to A.R.Z Pharma for ₹5.83 Crore
Acutaas Chemicals Limited has reduced its stake in its subsidiary, Acutaas Chemicals Electrolytes Private Limited (ACEPL), from 100% to 90%. This dilution occurred as ACEPL issued 1,111 new equity shares to a strategic investor, A.R.Z Pharma Ltd, at a high valuation of Rs. 52,490 per share. The total capital being raised at the subsidiary level is approximately Rs. 5.83 crore, with 25% paid upfront and the balance due within 12 months. Acutaas Chemicals retains full management control of the subsidiary despite the stake reduction.
முக்கிய அம்சங்கள்
Subsidiary ACEPL issued 1,111 equity shares to A.R.Z Pharma Ltd on a preferential basis.Shares issued at a significant premium of Rs. 52,480 per share, totaling Rs. 52,490 per share.Total transaction value is approximately Rs. 5.83 crore, with Rs. 1.46 crore called up immediately.Acutaas Chemicals Limited's shareholding in ACEPL decreased from 100% to 90%.The parent company retains full management and operational control of the subsidiary.
👀 கவனிக்க வேண்டியவை
Investors should note the high valuation at which the subsidiary raised capital, which serves as a positive benchmark for the company's electrolyte business. Monitor the strategic benefits and potential synergies arising from the partnership with Israel-based A.R.Z Pharma.
Acutaas Chemicals Outlines ₹1,000+ Cr Capex Plan and Dominant 50-90% Market Share in Key Segments
Acutaas Chemicals (formerly Ami Organics) has reported a strong performance with FY26 Pharma revenue reaching ₹11,741 Mn and total sales surpassing ₹10,000 Mn in 2025. The company is aggressively expanding with a ₹1,000+ Cr capex plan through FY30, focusing on high-entry-barrier markets like Semiconductor and Battery chemicals. It holds a dominant 50-90% global market share in key pharmaceutical intermediates and is the first Indian manufacturer of electrolyte additives. While the battery segment is yet to generate commercial revenue, it has 10+ products in the pipeline and 5+ customer validations.
முக்கிய அம்சங்கள்
Pharma segment revenue reached ₹11,741 Mn in FY26 with 50-90% global market share in key intermediates.Executing a ₹1,000+ Cr capex plan (FY23-FY30), including ₹220 Cr for battery chemicals and ₹200 Cr for semiconductors.Pioneering as India's first electrolyte additives manufacturer and only domestic producer of photoresist chemicals.Surpassed ₹10,000 Mn in total sales in 2025, rebranding from Ami Organics to reflect specialty chemical focus.Installed 16 MW solar capacity to meet the majority of electricity requirements across key facilities.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercialization timeline of the battery and semiconductor segments as they represent high-margin growth levers. The company's dominant position in chronic therapy pharma intermediates provides a stable cash flow base to fund these high-tech expansions.
Acutaas Chemicals Reports Record FY26 PAT of ₹356 Cr; Guides 25% Revenue Growth for FY27
Acutaas Chemicals delivered a robust FY26 performance with revenue growing 33% YoY to ₹1,339.4 crores and PAT more than doubling to ₹356.4 crores. The company is successfully diversifying into high-growth verticals like battery chemicals and semiconductors, with two new battery products expected to commercialize in FY27. Management has provided a confident 25% revenue growth guidance for FY27, supported by a strong CDMO pipeline and a planned 10x expansion of R&D capabilities. Despite global supply chain volatility, the company achieved a high Q4 EBITDA margin of 42.4%.
முக்கிய அம்சங்கள்
FY26 Revenue increased 33% YoY to ₹1,339.4 crores, with Q4 revenue rising 40.3% to ₹432.8 crores.Full-year PAT reached a record ₹356.4 crores, representing a growth of over 100% compared to the previous year.Q4 EBITDA margins expanded to 42.4%, driven by a 1,467 bps improvement in gross margins due to a better product mix.Invested ₹190 crores in South Korea JV (Indichem) and ₹195 crores in domestic capex for battery chemicals and pilot plants.Announced a 10x capacity expansion of the R&D center to support specialized divisions in pharma, semiconductors, and electronics.
👀 கவனிக்க வேண்டியவை
Investors should maintain a positive outlook given the strong earnings beat and clear 25% growth guidance. Monitor the successful commercialization of the battery chemical and semiconductor verticals as they evolve into independent growth engines by FY28.
Acutaas Chemicals Recommends Final Dividend of Rs 2.5 Per Share for FY 2025-26
The Board of Directors of Acutaas Chemicals Limited has recommended a final dividend of Rs 2.5 per equity share for the financial year 2025-26. This represents a 50% payout on the face value of Rs 5 per share. The dividend will be distributed across 8,18,71,122 equity shares, pending approval from shareholders at the upcoming 19th Annual General Meeting. Record and payout dates will be announced by the company in due course.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs 2.5 per equity share for FY 2025-26Dividend rate stands at 50% of the face value of Rs 5 per shareTotal number of eligible equity shares is 8,18,71,122Subject to shareholder confirmation at the 19th Annual General Meeting
👀 கவனிக்க வேண்டியவை
Investors should hold the stock to be eligible for the dividend and watch for the announcement of the record date. The 50% dividend payout reflects a positive return to shareholders for the fiscal year.
Acutaas Chemicals FY26 PAT Surges 122% to ₹3,564 Mn; Q4 Margins Hit Record 31%
Acutaas Chemicals (formerly Ami Organics) delivered exceptional FY26 results, with annual revenue rising 33% to ₹13,394 million. Net profit for the year surged 122% to ₹3,564 million, supported by a massive expansion in EBITDA margins to 35.9%. The company achieved its highest-ever quarterly PAT margin of 31% in Q4 FY26, driven by strong growth in the Pharma CDMO and Semiconductor businesses. Management has guided for a robust 25% revenue growth in FY27, focusing on high-growth verticals like battery chemicals.
முக்கிய அம்சங்கள்
FY26 Revenue grew 33% YoY to ₹13,394 million, led by a 37.5% jump in Advance Intermediates.Annual PAT surged 122.2% to ₹3,564 million, while Q4 PAT rose 114.1% YoY to ₹1,343 million.EBITDA margins expanded significantly from 23.0% in FY25 to 35.9% in FY26.Return on Equity (ROE) jumped to 32.5% in FY26 compared to 15.1% in the previous year.Management provided a strong growth outlook of 25% revenue increase for FY27.
👀 கவனிக்க வேண்டியவை
The company demonstrates industry-leading margin expansion and high return ratios (ROCE of 39.3%). Investors should monitor the execution of the 25% growth guidance for FY27 as a key performance indicator.
Acutaas Chemicals Q4 PAT Surges 114% YoY to ₹1,343 Mn; FY27 Revenue Guidance at 25%
Acutaas Chemicals reported a stellar performance for Q4 FY26, with revenue growing 40.3% YoY to ₹4,328 million. Net profit (PAT) more than doubled, rising 114.1% YoY to ₹1,343 million, driven by significant margin expansion. EBITDA margins improved drastically to 42.4% from 27.5% in the previous year's quarter. For the full year FY26, the company achieved a PAT of ₹3,564 million, a 122.2% increase over FY25. Management has provided a confident outlook, guiding for 25% revenue growth in FY27.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue from operations grew 40.3% YoY to ₹4,328 millionQ4 PAT jumped 114.1% YoY to ₹1,343 million with record margins of 31.0%EBITDA for the quarter rose 116% YoY to ₹1,835 million, with margins expanding to 42.4%Full-year FY26 PAT reached ₹3,564 million, marking a 122.2% growth over FY25Management guided for 25% revenue growth in FY27, focusing on Battery Chemicals and Semiconductors
👀 கவனிக்க வேண்டியவை
Investors should consider the stock's strong momentum and margin expansion as a sign of successful diversification into high-value sectors. The 25% growth guidance for FY27 provides clear visibility for future earnings and justifies a positive outlook.
Acutaas Chemicals Recommends Rs 2.50 Dividend; Indichem INC Named Material Subsidiary
Acutaas Chemicals Limited (formerly Ami Organics) has approved its audited financial results for the fiscal year ended March 31, 2026. The Board recommended a final dividend of Rs 2.50 per equity share (50% of face value), pending shareholder approval. A significant development is the classification of step-down subsidiary Indichem INC as a 'Material Subsidiary' based on its financial performance. The company also refreshed its audit team by appointing new internal and cost auditors for the 2026-27 fiscal year.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs 2.50 per equity share of Rs 5 face value (50% payout).Dividend to be distributed across 8,18,71,122 equity shares subject to AGM approval.Indichem INC identified as a Material Subsidiary, indicating a significant contribution to consolidated financials.M/s K. C Mehta & Co. LLP appointed as Internal Auditors for the financial year 2026-27.Audited Standalone and Consolidated Financial Results for FY 2025-26 approved by the Board.
👀 கவனிக்க வேண்டியவை
Investors should note the dividend yield and the growing importance of the US-based subsidiary Indichem INC. Monitor the full financial statement for specific revenue and profit growth figures compared to the previous year.
Acutaas Chemicals Completes 75% Acquisition of South Korean Semiconductor Chemical Firm Indichem
Acutaas Chemicals, through its wholly owned subsidiary Acutaas Advance Material Limited, has completed the acquisition of a 75% controlling stake in South Korean firm Indichem Inc. Indichem is a newly incorporated entity specializing in the semiconductor chemicals industry, providing Acutaas with a strategic entry into this high-growth global market. The acquisition involved 300,000 shares at a par value of KRW 500 each plus a share premium. Indichem is currently constructing a manufacturing plant in South Korea, which is scheduled for commissioning by the end of the 2025 calendar year.
முக்கிய அம்சங்கள்
Acquired 75% controlling stake (300,000 shares) in South Korean firm Indichem Inc.Target entity operates in the specialized semiconductor chemicals industry.Acquisition price set at KRW 500 per share par value plus applicable share premium.Manufacturing plant in South Korea is slated for commissioning by the end of 2025.Indichem Inc. now becomes a step-down subsidiary of Acutaas Chemicals Limited.
👀 கவனிக்க வேண்டியவை
This acquisition is a strategic move into the high-margin semiconductor value chain. Investors should monitor the timely commissioning of the South Korean facility by late 2025 as it will be the primary driver for revenue from this new segment.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
